Targeting inflammation to treat diabetic kidney disease: the road to 2030-Reference-Cited by-同舟云学术

Targeting inflammation to treat diabetic kidney disease: the road to 2030

Published:2023-02 Issue:2 Volume:103 Page:282-296
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Rayego-Mateos Sandra,Rodrigues-Diez Raul R,Fernandez-Fernandez Beatriz,Mora-Fernández Carmen,Marchant Vanessa,Donate-Correa Javier,Navarro-González Juan F.,Ortiz Alberto,Ruiz-Ortega Marta

Funder

Universidad Autonoma de Madrid

Publisher

Elsevier BV

Subject

Nephrology

Reference179 articles.

1. RICORS2040: the need for collaborative research in chronic kidney disease

2. Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline;Navaneethan;Ann Intern Med,2021

3. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes–2022;Draznin;Diabetes Care,2022

4. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia;Fernandez-Fernandez;Clin Kidney J,2020

5. Ortiz A, Ferro CJ, Balafa O, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. Published online May 4, 2021. https://doi.org/10.1093/ndt/gfab167

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The mechanisms underlying Chinese medicines to treat inflammation in diabetic kidney disease;Journal of Ethnopharmacology;2024-10

2. Biomarkers of Arginine Methylation in Diabetic Nephropathy: Novel Insights from Bioinformatics Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-09

3. Compositional Analysis and Network Pharmacological Strategy for the Treatment of Diabetic Kidney Disease by Shengjiang Powder Based on UHPLC-Q-TOF-MS;Natural Product Communications;2024-09

4. Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease;Diabetic Medicine;2024-08-27

5. Pentoxifylline ameliorates subclinical atherosclerosis progression in patients with type 2 diabetes and chronic kidney disease: a randomized pilot trial;Cardiovascular Diabetology;2024-08-24